TCR-engineered T-cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer

Overview of attention for article published in Cancer Discovery, August 2024

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

news: 3 news outlets
blogs: 1 blog

twitter: 4 X users

Readers on

mendeley: 11 Mendeley

Summary News Blogs X

So far, Altmetric has seen 2 posts from 1 blogs.

TCR-Engineered T-Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer

Stemcell science news, 30 Aug 2024

Scientists discovered Ropporin-1 (ROPN1) as a target to treat triple-negative breast cancer (TNBC) with T-cells. ROPN1 showed…

TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer

Stemcell science news, 22 Aug 2024

Scientists discovered Ropporin-1 (ROPN1) as a target for treating TNBC with T cells. ROPN1 showed high and homogenous…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.